Boston Scientific Received FDA Approval For The Expanded Indication of INGEVITY™+ Pacing Leads, Allowing For Conduction System Pacing in The Left Bundle Branch Area
On September 17, 2024, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval to expand the indication for the current-generation INGEVITY™+ Pacing Leads, which are thin wires placed inside the heart and connected to an implantable device. The approval now includes conduction system pacing (CSP) and sensing of the left bundle branch area (LBBA) when connected to a single- or dual-chamber pacemaker.
Pacing of the LBBA was introduced as an alternative to tradition...
